Scarica l'app Stockscreener
132.14
0.38%
0.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating - MSN
Is Neurocrine Biosciences Inc. stock overhyped or has real potentialExponential wealth increase - jammulinksnews.com
10 Best Strong Buy Healthcare Stocks to Buy Now - Insider Monkey
Is Neurocrine Biosciences Inc. a good long term investmentRecord-breaking gains - Autocar Professional
Neurocrine Biosciences (NASDAQ:NBIX) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
11 Best Long Term Low Risk Stocks to Invest in - Insider Monkey
What analysts say about Neurocrine Biosciences Inc. stockDynamic investment opportunities - Autocar Professional
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Neurocrine Bio. stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Canada
What drives Neurocrine Biosciences Inc. stock priceRapidly growing investment returns - jammulinksnews.com
Neurocrine Biosciences Inc. Stock Analysis and ForecastExponential wealth increase - jammulinksnews.com
Truist Securities Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation - MSN
Lobbying Update: $890,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative
Truist Securities initiates Neurocrine Bio stock with Buy rating on Crenessity potential - Investing.com Canada
Daily Turnover | The turnover of Neurocrine Biosciences on 7/18 was $100.31 Million, Ranking 820 - AInvest
Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - simplywall.st
Neurocrine Biosciences’ NBI-921352 Study: A Potential Game-Changer for SCN8A-DEE Treatment - TipRanks
Lobbying Update: $80,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed - Nasdaq
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewswire Inc.
Neurocrine reports positive results from Crenessity trial - MSN
Neurocrine Biosciences shares rise 2.09% after-hours after presenting new analysis on CAH treatment. - AInvest
Neurocrine shares new one-year data from trial of Crenessity for CAH - Yahoo Finance
Groundbreaking AI Research Exposes Lifelong Treatment Challenges for Rare CAH Patients - Stock Titan
Neurocrine shares registry data showing CAH treatment challenges - StreetInsider
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 - PR Newswire
New weight reduction data for Crenessity presented by Neurocrine - The Pharma Letter
Wedbush Raises Price Target on Neurocrine Biosciences to $137 From $130, Keeps Outperform Rating - MarketScreener
What makes Neurocrine Biosciences Inc. stock price move sharplyMassive Upside Selection - beatles.ru
NBIX : Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients - Nasdaq
Endometriosis Market to Reach New Heights in Growth by 2034, - openPR.com
Neurocrine Biosciences CRENESSITY Shows Clinically Meaningful Weight Loss And Insulin Resistance Improvement In Adults And Children With CAH In Phase 3 Trials, Presented At ENDO 2025 - 富途牛牛
Neurocrine presents one-year data showing weight improvements with CRENESSITY - StreetInsider
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting - Eastern Progress
Neurocrine presents one-year CRENESSITY data at ENDO 2025 conference - StreetInsider
Neurocrine Biosciences Reports Positive 1-year Data Of Crenessity In Adults With CAH At ENDO 2025 - Nasdaq
Neurocrine Biosciences: CRENESSITY's Breakthrough in CAH Positions NBIX for Sustained Growth - AInvest
Neurocrine reports positive results from Crenessity trial (NBIX) - Seeking Alpha
0.62%
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):